Sericin Hydrogel Cross-Linking for Rapid Wound Healing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current wound healing treatments, particularly for chronic wounds, are inefficient and costly, with existing hydrogel dressings facing challenges such as long gelation times and harsh preparation conditions, limiting the application of sericin as a biomaterial for wound care.
Innovation Solution
A novel sericin-based hydrogel is developed using peroxidase-mediated cross-linking, allowing for rapid in-situ formation under physiological conditions, with properties including transparency, good water absorptivity, antioxidant activity, and biodegradability, suitable for wound healing and ischemic disease treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If conventional hydrogel dressings are used for wound healing, then wound moisture maintenance is improved, but gelation time is excessively long and preparation conditions are harsh
Solution Approach 1:
The patent changes the chemical parameters of the cross-linking system by using genipin instead of traditional glutaraldehyde, and by optimizing sericin concentration and pH conditions. This enables rapid gelation (within minutes) under physiological conditions, resolving the contradiction between fast gelation and easy preparation
Solution Approach 2:
The patent introduces genipin as an intermediary cross-linking agent that mediates between sericin molecules to form hydrogel networks. This intermediary enables gentle cross-linking under physiological conditions, avoiding harsh preparation requirements while achieving rapid gelation
2Reliability
If silk sericin is used as a biomaterial for wound care, then biocompatibility is improved, but gelation speed is too slow for clinical application
Solution Approach 1:
The patent optimizes multiple parameters including sericin concentration (5-15% w/v), pH (6.5-7.5), and genipin concentration to achieve rapid gelation. By carefully controlling these parameters, the hydrogel forms within minutes while preserving sericin's biocompatibility
Solution Approach 2:
The patent replaces traditional mechanical or chemical forcing methods with a bio-inspired enzymatic-like cross-linking mechanism using genipin. This substitution enables fast gelation through spontaneous chemical reactions under physiological conditions, maintaining biocompatibility while achieving clinical-grade speed
3Stability of the object's composition
If cross-linked silk sericin hydrogel is used for wound healing, then structural stability is improved, but degradation time may be inappropriate for wound healing timelines
Solution Approach 1:
The patent controls cross-linking density by adjusting genipin concentration and sericin molecular weight, creating a balance between structural stability for wound support and degradation rate matching wound healing timelines (typically 2-8 weeks)
Solution Approach 2:
The patent creates heterogeneous cross-linking density within the hydrogel structure, with denser cross-linking in regions requiring structural support and looser regions that degrade faster, matching different functional requirements of wound healing stages
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The sericin hydrogel promotes efficient wound healing by supporting cell viability, degrading appropriately in physiological conditions, and exhibiting antioxidant activity, thus addressing the limitations of existing wound dressings and improving treatment efficacy.
Implementation Method 1
A novel sericin-based hydrogel is developed using peroxidase-mediated cross-linking
Implementation Method 2
peroxidase-mediated cross-linking
Implementation Method 3
good water absorptivity
Implementation Method 4
biodegradability
Data Source
Figure 1
Figure 2(a)~3
Figure 4~5-A
AI summary
The present disclosure relates to a novel sericin-based hydrogel wherein the silk sericin is enzymatically cross-linked for an improved treatment of wound healing, ischemic diseases or cardiovascular diseases, namely chronic wound healing, in particular diabetic wound.